Rhenman & Partners Asset Management Ab Apellis Pharmaceuticals, Inc. Transaction History

Rhenman & Partners Asset Management Ab

$766 Million
Q2 2025

A detailed history of Rhenman & Partners Asset Management Ab transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Rhenman & Partners Asset Management Ab holds 93,250 shares of APLS stock, worth $1.91 Million. This represents 0.21% of its overall portfolio holdings.

Number of Shares

93,250

Previous 28,250 230.09%

Holding current value

$1.91 Million

Previous $617,000 161.59%

% of portfolio

0.21%

Previous 0.07%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 13, 2025	BUY	$16.36 - $23.0 $1.06 Million - $1.5 Million	65,000 Added 230.09%	93,250 $1.61 Million
Q1 2025 May 14, 2025	SELL	$21.87 - $34.63 $3.66 Million - $5.8 Million	-167,341 Reduced 85.56%	28,250 $617,000
Q4 2024 Feb 13, 2025	SELL	$26.18 - $35.42 $4.5 Million - $6.09 Million	-171,909 Reduced 46.78%	195,591 $6.24 Million
Q3 2024 Nov 13, 2024	BUY	$28.84 - $41.15 $9 Million - $12.8 Million	312,105 Added 563.42%	367,500 $10.6 Million
Q2 2024 Aug 13, 2024	SELL	$38.07 - $59.71 $4.68 Million - $7.34 Million	-123,000 Reduced 68.95%	55,395 $2.12 Million
Q1 2024 May 14, 2024	BUY	$55.39 - $72.47 $4.32 Million - $5.65 Million	77,995 Added 77.68%	178,395 $10.5 Million
Q4 2023 Feb 13, 2024	SELL	$37.14 - $64.82 $4.26 Million - $7.43 Million	-114,600 Reduced 53.3%	100,400 $6.01 Million
Q3 2023 Nov 13, 2023	BUY	$23.65 - $89.22 $591,250 - $2.23 Million	25,000 Added 13.16%	215,000 $8.18 Million
Q2 2023 Aug 11, 2023	BUY	$76.68 - $93.31 $383,400 - $466,550	5,000 Added 2.7%	190,000 $17.3 Million
Q1 2023 May 11, 2023	SELL	$46.59 - $66.96 $698,850 - $1 Million	-15,000 Reduced 7.5%	185,000 $12.2 Million
Q4 2022 Feb 13, 2023	SELL	$43.24 - $61.04 $864,800 - $1.22 Million	-20,000 Reduced 9.09%	200,000 $10.3 Million
Q3 2022 Nov 14, 2022	BUY	$44.76 - $69.66 $447,600 - $696,600	10,000 Added 4.76%	220,000 $13.3 Million
Q2 2022 Aug 12, 2022	SELL	$35.07 - $59.21 $5.86 Million - $9.89 Million	-167,000 Reduced 44.3%	210,000 $9.5 Million
Q1 2022 May 13, 2022	SELL	$35.46 - $54.12 $1.88 Million - $2.87 Million	-53,000 Reduced 12.33%	377,000 $19.2 Million
Q4 2021 Feb 11, 2022	SELL	$30.74 - $49.16 $4.04 Million - $6.45 Million	-131,269 Reduced 23.39%	430,000 $20.6 Million
Q3 2021 Nov 12, 2021	BUY	$31.4 - $69.84 $8.05 Million - $17.9 Million	256,269 Added 84.02%	561,269 $18.5 Million
Q2 2021 Aug 13, 2021	BUY	$40.9 - $64.9 $1.43 Million - $2.27 Million	35,000 Added 12.96%	305,000 $19.3 Million
Q4 2020 Jan 19, 2021	BUY	$30.79 - $57.2 $1.39 Million - $2.57 Million	45,000 Added 20.0%	270,000 $15.4 Million
Q3 2020 Oct 13, 2020	BUY	$25.89 - $33.65 $1.55 Million - $2.02 Million	60,000 Added 36.36%	225,000 $6.79 Million
Q2 2020 Jul 16, 2020	BUY	$24.8 - $38.49 $1.61 Million - $2.5 Million	65,000 Added 65.0%	165,000 $5.39 Million
Q1 2020 Apr 16, 2020	BUY	$17.91 - $44.33 $358,200 - $886,600	20,000 Added 25.0%	100,000 $2.68 Million
Q4 2019 Jan 17, 2020	BUY	$22.1 - $30.8 $1.77 Million - $2.46 Million	80,000 New	80,000 $2.45 Million

Others Institutions Holding APLS

# of Institutions

304

Shares Held

134M

Call Options Held

2.97M

Put Options Held

623K

View Full List

About Apellis Pharmaceuticals, Inc.

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $2.25B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

More about APLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhenman & Partners Asset Management Ab, based on Form 13F filings with the SEC.

News

Stay updated on Rhenman & Partners Asset Management Ab with notifications on news.

Account

Rhenman & Partners Asset Management Ab Apellis Pharmaceuticals, Inc. Transaction History